0000950170-24-084299.txt : 20240717 0000950170-24-084299.hdr.sgml : 20240717 20240717163012 ACCESSION NUMBER: 0000950170-24-084299 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240715 FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SKYLER JAY S CENTRAL INDEX KEY: 0001236386 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39871 FILM NUMBER: 241122583 MAIL ADDRESS: STREET 1: DANCE BIOPHARM INC. STREET 2: 150 NORTH HILL DRIVE, SUITE 24 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 W 41ST ST STREET 2: SUITE 401 CITY: MIAMI BEACH STATE: FL ZIP: 33140 BUSINESS PHONE: 305-845-2813 MAIL ADDRESS: STREET 1: 777 W 41ST ST STREET 2: SUITE 401 CITY: MIAMI BEACH STATE: FL ZIP: 33140 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 4 1 ownership.xml 4 X0508 4 2024-07-15 0001833214 SAB Biotherapeutics, Inc. SABS 0001236386 SKYLER JAY S 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 true false false false false Stock Option (right to buy) 2.90 2024-07-15 4 A false 20000 0 A 2034-07-15 Common Stock 20000 20000 D Stock Option (right to buy) 2.90 2024-07-15 4 A false 35000 0 A 2034-07-15 Common Stock 35000 35000 D Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026. Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on May 3, 2025, 2026, and 2027. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. /s/ Jay S. Skyler 2024-07-17